HC Wainwright Issues Optimistic Estimate for MIRM Earnings

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) – Investment analysts at HC Wainwright raised their Q3 2026 earnings per share (EPS) estimates for shares of Mirum Pharmaceuticals in a research note issued on Thursday, August 6th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.31) per share for the quarter, up from their prior forecast of ($1.06). HC Wainwright has a “Buy” rating and a $140.00 price objective on the stock. The consensus estimate for Mirum Pharmaceuticals’ current full-year earnings is ($1.24) per share. HC Wainwright also issued estimates for Mirum Pharmaceuticals’ Q4 2026 earnings at ($0.12) EPS, Q1 2027 earnings at $0.08 EPS, Q2 2027 earnings at $0.16 EPS, Q3 2027 earnings at $0.40 EPS, Q4 2027 earnings at $0.64 EPS, FY2027 earnings at $1.28 EPS, FY2028 earnings at $3.96 EPS, FY2029 earnings at $5.71 EPS and FY2030 earnings at $7.12 EPS.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, August 5th. The company reported ($1.06) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.32). The business had revenue of $176.24 million for the quarter, compared to the consensus estimate of $166.33 million. Mirum Pharmaceuticals had a negative return on equity of 36.28% and a negative net margin of 139.18%.The company’s revenue for the quarter was up 37.9% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.12) earnings per share.

Other analysts have also issued research reports about the stock. Wall Street Zen raised shares of Mirum Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday. Stifel Nicolaus set a $136.00 target price on shares of Mirum Pharmaceuticals in a research report on Thursday, May 7th. Citizens Jmp decreased their price target on shares of Mirum Pharmaceuticals from $146.00 to $137.00 and set a “market outperform” rating for the company in a research note on Thursday, August 6th. Wolfe Research started coverage on shares of Mirum Pharmaceuticals in a report on Tuesday, May 19th. They issued an “outperform” rating and a $145.00 price target on the stock. Finally, Robert W. Baird set a $123.00 price objective on Mirum Pharmaceuticals in a research note on Thursday, August 6th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Mirum Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $137.33.

Mirum Pharmaceuticals Price Performance

MIRM opened at $98.23 on Monday. Mirum Pharmaceuticals has a fifty-two week low of $63.23 and a fifty-two week high of $130.00. The firm has a 50-day moving average of $110.50 and a 200 day moving average of $101.94. The company has a debt-to-equity ratio of 1.28, a quick ratio of 2.74 and a current ratio of 2.86. The firm has a market cap of $6.38 billion, a P/E ratio of -6.75 and a beta of 0.52.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of MIRM. Cullen Frost Bankers Inc. bought a new stake in Mirum Pharmaceuticals during the 4th quarter valued at $30,000. Eurizon Capital SGR S.p.A. bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at $32,000. CIBC Private Wealth Group LLC bought a new stake in shares of Mirum Pharmaceuticals during the 4th quarter valued at $32,000. State of Wyoming purchased a new stake in Mirum Pharmaceuticals during the 2nd quarter worth about $52,000. Finally, Quantbot Technologies LP purchased a new stake in Mirum Pharmaceuticals during the 3rd quarter worth about $33,000.

Insider Buying and Selling at Mirum Pharmaceuticals

In other news, SVP Jolanda Howe sold 1,840 shares of Mirum Pharmaceuticals stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $105.29, for a total value of $193,733.60. Following the completion of the transaction, the senior vice president owned 1,274 shares in the company, valued at $134,139.46. This trade represents a 59.09% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Christopher Peetz sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $98.92, for a total transaction of $1,978,400.00. Following the completion of the sale, the chief executive officer directly owned 194,309 shares in the company, valued at approximately $19,221,046.28. This trade represents a 9.33% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 87,155 shares of company stock valued at $9,164,062 over the last three months. 8.32% of the stock is currently owned by insiders.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.